Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Blood advances·2026
Same author

Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE.

Clinical Medicine Insights. Cardiology·2026
Same author

Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.

Blood cancer journal·2026
Same author

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Hepatic response criteria in light chain amyloidosis: a multicenter validation study.

Haematologica·2026

Related Experiment Video

Updated: Jun 6, 2026

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

Plasma cell leukemia: concepts and management.

Michaela Liedtke1, Bruno C Medeiros

  • 1Department of Medicine, Division of Hematology, Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2329, Stanford, CA 94305-5821, USA.

Expert Review of Hematology
|November 19, 2010
PubMed
Summary

Plasma cell leukemia (PCL) is a rare, aggressive cancer with a poor prognosis. Emerging treatments show potential to improve survival for PCL patients.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia.
  • Patients with PCL exhibit a very poor prognosis, with median survival measured in months.
  • PCL can arise de novo or after a history of plasma cell myeloma.

Purpose of the Study:

  • To summarize the clinical features, prognosis, and treatment landscape of plasma cell leukemia.
  • To discuss the potential impact of novel therapeutic agents and stem cell transplantation on PCL outcomes.

Main Methods:

  • Review of existing literature on plasma cell leukemia.
  • Analysis of clinical presentation, immunophenotypic markers, and treatment strategies.
  • Evaluation of emerging data on newer agents and transplantation.

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Experiment Videos

Last Updated: Jun 6, 2026

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Main Results:

  • PCL patients often present with aggressive features like extramedullary disease, bone marrow failure, and advanced stage.
  • Distinct immunophenotypic markers, including CD56 negativity and CD20 positivity, are common in PCL.
  • Historically, palliative treatment has been the norm, with limited durable remissions.

Conclusions:

  • The prognosis for PCL remains very poor, with limited treatment options offering durable remission.
  • Novel agents like bortezomib and lenalidomide, combined with stem cell transplantation, are being investigated.
  • Emerging data suggest these newer modalities may offer improved outcomes for PCL patients.